| Name | Title | Contact Details |
|---|
Squip is a Lebanon, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lifeclinic International, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Burtonsville, MD. To find more information about Lifeclinic International, Inc., please visit www.lifeclinic.com
Health Union integrates the power of human connection with technology to unite people in the shared experiences of life with chronic health conditions. For almost a decade, Health Union has done the hard work every day to bring people living with chronic conditions together. Through a unique and genuine approach to listening and understanding all aspects of health experiences, Health Union`s open, online communities provide a safe place for people to learn, connect and share. In doing so, social interactions evolve into meaningful health conversations. At the same time, these communities offer healthcare companies countless opportunities to understand how to reach and engage people living with these conditions in smarter, more effective ways. Today, the Health Union family of brands includes online health communities for chronic conditions in a range of categories including primary care, immunology, oncology and neurodegenerative/genetic conditions. Among them are Migraine.com, MultipleSclerosis.net, Endometriosis.net and LungCancer.net to name a few. Health Union is dedicated to making an impact on the lives of people with chronic health concerns. In 2018, that focus has been recognized. The company was named among the top 15 percent of the Inc. 5000 list of fastest-growing private companies in America and topped the list of both Philly.com`s “Top Workplaces” and Philadelphia Business Journal`s “Best Places to Work.”
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."